BL Wang, SB Kou, ZY Lin, JH Shi, YX Liu - International journal of …, 2020 - Elsevier
Brigatinib, a multi-target kinase inhibitor, is primarily used to treat anaplastic lymphoma
kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC) who have …